Who founded Grey Wolf Therapeutics?

Grey Wolf Therapeutics was founded by Peter Joyce, Tom McCarthy in 2017.

Who are Grey Wolf Therapeutics's investors?

Grey Wolf Therapeutics's investors include Andera Partners, Canaan Partners, Oxford Science Enterprises, Pfizer Venture Investments, British Patient Capital, Earlybird Venture Capital, Pfizer Ventures.

How much funding has Grey Wolf Therapeutics raised?

Grey Wolf Therapeutics has disclosed $99M raised across 2 rounds.

Where is Grey Wolf Therapeutics headquartered?

Grey Wolf Therapeutics is headquartered in Oxford, GB.

Grey Wolf Therapeutics

Oxford, GB · Founded 2017 · 57 employees on LinkedIn · 11 known investors

Find your way into Grey Wolf Therapeutics

103 people in our graph share verified history with the Grey Wolf Therapeutics team — schools, employers, funds. One of them is your warm intro.

Thomas Rubensunlockedknows Peter Joyce · together at University of Bristol (overlapped)

×10knows the team · via University of Bristol

knows the team · via Medical Research Council, Mammalian Genetics Unit

Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.

Biotech Digital Health Healthtech Medical Devices

Founders & leadership

Grey Wolf Therapeutics was founded in 2017 by Peter Joyce and Tom McCarthy.

Peter Joyce inCo-founderPeter Joyce is co-founder of Grey Wolf Therapeutics and has prior experience in drug discovery across oncology, neurodegeneration, and rare diseases in both industrial and academic settings.

Tom McCarthyinCo-founder

Investors · 11

Andera PartnersParis

Canaan PartnersStamford · $500K – $20M

Oxford Science EnterprisesOxford · $63.5K – $31.8M

Pfizer Venture Investments$5M – $20M

British Patient CapitalreportedLondon

Earlybird Venture CapitalreportedBerlin · $540K – $12M

Pfizer Venturesreported

Also in the syndicate · 4

CanaanICGleadICG Life Sciences TeamleadICG's Life Sciences teamlead

Funding

SEC filings, press & company announcements

$99M disclosed across 2 rounds · 2023–2024

$50MSeries BMay 2024 · 4 sources
ICG (lead), ICG Life Sciences Team (lead), ICG's Life Sciences team (lead), Andera Partners, British Patient Capital, Canaan, Earlybird Venture Capital, Oxford Science Enterprises, Pfizer Ventures
Source ↗
$49MSeries BJan 2023 · 2 sources
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Founder mafia

2 people who came through Grey Wolf Therapeutics went on to found or lead other companies.

Peter JoyceCo-founderFounded Pathios Therapeutics Rachel HumphreyScientific Advisory Board MemberFounded Normunity

Competitors · 1

by search overlap

Werewolf Therapeutics11 shared keywordsWerewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer. The company focuses on leveraging immune modulation and innovative therapeutic approaches in oncology.

Companies competing with Grey Wolf Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Companies House · registry record

View on Companies House ↗

Registered name: GREY WOLF THERAPEUTICS LIMITED
Company number: 10989365
Status: Active
Company type: Private limited company
Incorporated: 29 Sept 2017
Registered office: 99 Park Drive, Milton, Abingdon, OX14 4RY
Nature of business (SIC): 72110 — Research and experimental development on biotechnology
Accounts: last made up to 31 Dec 2024 · next due 30 Sept 2026
Confirmation statement: last made up to 27 Oct 2025 · next due 10 Nov 2026

Current officers · 11

Paul John Grattan Stainer — secretary, appointed 1 May 2025
Brenton Karl Ahrens — director, appointed 29 Mar 2018
Thierry Hercend — director, appointed 29 Mar 2018
Peter Joyce — director, appointed 29 Sept 2017
Allan Patrick Marchington — director, appointed 2 Mar 2026
Thomas David Mccarthy — director, appointed 29 Sept 2017
Edwin Moses — director, appointed 16 Apr 2026
Rabab Nasrallah — director, appointed 23 Dec 2022
Marie-Claire Peakman — director, appointed 23 Dec 2022
Ekaterina Smirnyagina — director, appointed 25 Nov 2024
Raphael Wisniewski — director, appointed 29 Mar 2018

Source: Companies House public register · retrieved 16 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Grey Wolf Therapeutics funding news - Clinical-stage Biotechnology Company Grey Wolf Therapeutics Secures $50 Million in Series B Round Fundingstartuprise.co.uk · May 2024

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technologyprnewswire.com · May 2024

UK-based Grey Wolf Therapeutics raises €46 million Series B to develop disease-modifying therapies for autoimmune disorders | EU-Startupseu-startups.com · May 2024

Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion - ICGicgam.com · May 2024

Grey Wolf Therapeutics Closes Oversubscribed $49 Million Series B Financing to Advance First-of-its-Kind Neoantigen Creation Approachesprnewswire.com · Jan 2023

Grey Wolf Therapeutics Closes $49M Series B Financingfinsmes.com · Jan 2023

Frequently asked questions

What does Grey Wolf Therapeutics do?: Greywolf is a clinical-stage biotech developing antigen modulation therapies, including oral small molecules in Phase 1/2 trials, for people with cancers and autoimmune disorders.
Who founded Grey Wolf Therapeutics?: Grey Wolf Therapeutics was founded by Peter Joyce, Tom McCarthy in 2017.
Who are Grey Wolf Therapeutics's investors?: Grey Wolf Therapeutics's investors include Andera Partners, Canaan Partners, Oxford Science Enterprises, Pfizer Venture Investments, British Patient Capital, Earlybird Venture Capital, Pfizer Ventures.
How much funding has Grey Wolf Therapeutics raised?: Grey Wolf Therapeutics has disclosed $99M raised across 2 rounds.
Where is Grey Wolf Therapeutics headquartered?: Grey Wolf Therapeutics is headquartered in Oxford, GB.